Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors
NCT07279532Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in neuroendocrine tumors (NETs), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT07279532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279532.